Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating reissued by Liberum Capital in a research note issued to investors on Thursday. They currently have a GBX 245 ($3.16) price target on the stock. Liberum Capital’s price objective would suggest a potential upside of 55.56% from the stock’s previous close.

Several other brokerages have also recently commented on STX. FinnCap started coverage on Shield Therapeutics PLC in a research report on Thursday, September 7th. They set a “buy” rating and a GBX 270 ($3.49) price target for the company. Peel Hunt reiterated a “buy” rating and set a GBX 220 ($2.84) price target on shares of Shield Therapeutics PLC in a research report on Thursday, July 6th.

Shield Therapeutics PLC (LON STX) remained flat at GBX 157.50 during midday trading on Thursday. The company’s stock had a trading volume of 2,500 shares. The stock has a 50-day moving average price of GBX 157.50 and a 200-day moving average price of GBX 163.10. Shield Therapeutics PLC has a 52 week low of GBX 152.25 and a 52 week high of GBX 177.00. The firm’s market cap is GBX 170.10 million.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at

About Shield Therapeutics PLC

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.

Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with's FREE daily email newsletter.